Multidisciplinary Management of Metastatic Colorectal Cancer

    The management of metastatic cancers has changed significantly over the last decade with improved understanding of its underlying pathophysiology a...
    • Overview

      The management of metastatic cancers has changed significantly over the last decade with improved understanding of its underlying pathophysiology and signal pathways. However, a significant proportion of patients with metastatic colorectal cancer or metastatic squamous cell carcinoma of the head and neck has a poor prognosis, in many cases due to late presentation. For those patients, cure is typically not possible; treatment options can prolong life and improve symptoms.  Thus, long-term survival rates in these metastatic settings, while improving, remain unacceptably low.

      Despite advances, the management of patients with metastatic disease continues to present challenges for clinicians. As innovative focused therapeutic options become available and treatment paradigms evolve, the need to discern when and how to incorporate these promising agents into clinicians’ armamentarium presents a great educational need. Moreover, continuing advances in our understanding of cancer pathophysiology, molecular pathways, the optimal and sequential use of targeted therapies in the context of chemotherapy and radiotherapy in the metastatic setting and the therapeutic potential of investigational agents currently being explored for various cancers, suggest educational and clinical practice gaps that must be effectively addressed to further improve outcomes in patients with cancer.

      Given this information, Siyemi Learning in partnership with Prova Education, presents this module titled “Multidisciplinary Management of Metastatic Colorectal Cancer”. This module reviews current clinical practice guidelines, the role of anti-angiogenic and EGFR inhibitors, challenges in patients with liver metastases, methods to increase resectability, assessment of current treatment modalities, and the optimisation of an onco-surgical collaborative approach to the treatment of metastatic colorectal cancer.

    • Learning Objectives

      At the completion of this module, participants will be better able to:

      1. Identify and contrast international clinical practice guidelines for the treatment of metastatic colorectal cancer
      2. Explain the implications of the EGFR pathway in the development of metastatic colorectal cancer
      3. Assess the relative efficacy of chemotherapeutic and targeted agents in the treatment of metastatic colorectal cancer
      4. Explain treatment approaches that would increase resectability in patients with metastatic colorectal cancer, especially those with liver metastases
      5. Describe how the onco-surgical collaboration can improve outcomes in patients with metastatic colorectal cancer
    • Commercial Support

      This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.
       
      Original Release Date: 5 February 2015
      Expiration Date: 5 February 2017

    • Disclosure of Conflicts of Interest

      COURSE DIRECTOR

      Jan B. Vermorken, MD, PhD
      Emeritus Professor of Oncology
      Department of Medical Oncology 
      Antwerp University Hospital 
      Edegem, Belgium
      Financial Relationship Disclosure
      Consultant: Amgen, Genentech, Merck Serono, Shionogi      
      Commercial Interest Speakers Bureau: Merck Serono

      AUTHORS

      René Adam, MD, PhD
      President of the Medical Board of the Paul Brousse Hospital
      Head of the Oncological Surgery Unit of the Hepato Biliary Center
      Villejuif, France
      Financial Relationship Disclosure
      Consulting Fees: Amgen, Merck, Roche, Sanofi

      Fortunato Ciardiello, MD, PhD
      Professor of Medical Oncology
      Director of Dipartmento Medico
      Chirurgico di Internistica Clinica e Sperimentale
      Seconda Università degli Studi di Napoli
      Naples, Italy
      Financial Relationship Disclosure
      Consultant: Bayer HealthCare Pharmaceuticals, Merck Serono, Roche
      Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals

      REVIEWER

      Wafik S. El-Deiry, MD, PhD, FACP
      Rose Dunlap Professor and Chief, Hematology/Oncology
      Associate Director for Translational Research, Cancer Institute
      Penn State Hershey Medical Center
      Hershey, PA - USA 
      Financial Relationship Disclosure
      Receipt of Intellectual Property Rights: Morphotek, Oncoceutics, Inc.         
      Ownership Interest: Oncoceutics, Inc., p53-Therapeutics, Inc.

    Facebook Comments

    NEW FEATURES: